Cargando…

Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C(H)1-C(λ) interface

Bispecific antibodies represent an increasingly large fraction of biologics in therapeutic development due to their expanded scope in functional capabilities. Asymmetric monovalent bispecific IgGs (bsIgGs) have the additional advantage of maintaining a native antibody-like structure, which can provi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagert, John D., Oganesyan, Vaheh, Chiang, Chi-I, Iannotti, Mike, Lin, Jia, Yang, Chunning, Payne, Sterling, McMahon, Will, Edwards, Samuel, Dippel, Andrew, Hutchinson, Mark, Huang, Fengying, Aleti, Vineela, Niu, Chendi, Qian, Chen, Denham, Jessica, Ferreira, Sofia, Pradhan, Pallab, Penney, Mark, Wang, Chunlei, Liu, Wenhai, Walseng, Even, Mazor, Yariv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629431/
https://www.ncbi.nlm.nih.gov/pubmed/37930310
http://dx.doi.org/10.1080/19420862.2023.2273449
_version_ 1785131965799727104
author Bagert, John D.
Oganesyan, Vaheh
Chiang, Chi-I
Iannotti, Mike
Lin, Jia
Yang, Chunning
Payne, Sterling
McMahon, Will
Edwards, Samuel
Dippel, Andrew
Hutchinson, Mark
Huang, Fengying
Aleti, Vineela
Niu, Chendi
Qian, Chen
Denham, Jessica
Ferreira, Sofia
Pradhan, Pallab
Penney, Mark
Wang, Chunlei
Liu, Wenhai
Walseng, Even
Mazor, Yariv
author_facet Bagert, John D.
Oganesyan, Vaheh
Chiang, Chi-I
Iannotti, Mike
Lin, Jia
Yang, Chunning
Payne, Sterling
McMahon, Will
Edwards, Samuel
Dippel, Andrew
Hutchinson, Mark
Huang, Fengying
Aleti, Vineela
Niu, Chendi
Qian, Chen
Denham, Jessica
Ferreira, Sofia
Pradhan, Pallab
Penney, Mark
Wang, Chunlei
Liu, Wenhai
Walseng, Even
Mazor, Yariv
author_sort Bagert, John D.
collection PubMed
description Bispecific antibodies represent an increasingly large fraction of biologics in therapeutic development due to their expanded scope in functional capabilities. Asymmetric monovalent bispecific IgGs (bsIgGs) have the additional advantage of maintaining a native antibody-like structure, which can provide favorable pharmacology and pharmacokinetic profiles. The production of correctly assembled asymmetric monovalent bsIgGs, however, is a complex engineering endeavor due to the propensity for non-cognate heavy and light chains to mis-pair. Previously, we introduced the DuetMab platform as a general solution for the production of bsIgGs, which utilizes an engineered interchain disulfide bond in one of the C(H)1-C(L) domains to promote orthogonal chain pairing between heavy and light chains. While highly effective in promoting cognate heavy and light chain pairing, residual chain mispairing could be detected for specific combinations of Fv pairs. Here, we present enhancements to the DuetMab design that improve chain pairing and production through the introduction of novel electrostatic steering mutations at the C(H)1-C(L) interface with lambda light chains (C(H)1-C(λ)). These mutations work together with previously established charge-pair mutations at the C(H)1-C(L) interface with kappa light chains (C(H)1-C(κ)) and Fab disulfide engineering to promote cognate heavy and light chain pairing and enable the reliable production of bsIgGs. Importantly, these enhanced DuetMabs do not require engineering of the variable domains and are robust when applied to a panel of bsIgGs with diverse Fv sequences. We present a comprehensive biochemical, biophysical, and functional characterization of the resulting DuetMabs to demonstrate compatibility with industrial production benchmarks. Overall, this enhanced DuetMab platform substantially streamlines process development of these disruptive biotherapeutics.
format Online
Article
Text
id pubmed-10629431
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-106294312023-11-08 Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C(H)1-C(λ) interface Bagert, John D. Oganesyan, Vaheh Chiang, Chi-I Iannotti, Mike Lin, Jia Yang, Chunning Payne, Sterling McMahon, Will Edwards, Samuel Dippel, Andrew Hutchinson, Mark Huang, Fengying Aleti, Vineela Niu, Chendi Qian, Chen Denham, Jessica Ferreira, Sofia Pradhan, Pallab Penney, Mark Wang, Chunlei Liu, Wenhai Walseng, Even Mazor, Yariv MAbs Report Bispecific antibodies represent an increasingly large fraction of biologics in therapeutic development due to their expanded scope in functional capabilities. Asymmetric monovalent bispecific IgGs (bsIgGs) have the additional advantage of maintaining a native antibody-like structure, which can provide favorable pharmacology and pharmacokinetic profiles. The production of correctly assembled asymmetric monovalent bsIgGs, however, is a complex engineering endeavor due to the propensity for non-cognate heavy and light chains to mis-pair. Previously, we introduced the DuetMab platform as a general solution for the production of bsIgGs, which utilizes an engineered interchain disulfide bond in one of the C(H)1-C(L) domains to promote orthogonal chain pairing between heavy and light chains. While highly effective in promoting cognate heavy and light chain pairing, residual chain mispairing could be detected for specific combinations of Fv pairs. Here, we present enhancements to the DuetMab design that improve chain pairing and production through the introduction of novel electrostatic steering mutations at the C(H)1-C(L) interface with lambda light chains (C(H)1-C(λ)). These mutations work together with previously established charge-pair mutations at the C(H)1-C(L) interface with kappa light chains (C(H)1-C(κ)) and Fab disulfide engineering to promote cognate heavy and light chain pairing and enable the reliable production of bsIgGs. Importantly, these enhanced DuetMabs do not require engineering of the variable domains and are robust when applied to a panel of bsIgGs with diverse Fv sequences. We present a comprehensive biochemical, biophysical, and functional characterization of the resulting DuetMabs to demonstrate compatibility with industrial production benchmarks. Overall, this enhanced DuetMab platform substantially streamlines process development of these disruptive biotherapeutics. Taylor & Francis 2023-11-06 /pmc/articles/PMC10629431/ /pubmed/37930310 http://dx.doi.org/10.1080/19420862.2023.2273449 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Report
Bagert, John D.
Oganesyan, Vaheh
Chiang, Chi-I
Iannotti, Mike
Lin, Jia
Yang, Chunning
Payne, Sterling
McMahon, Will
Edwards, Samuel
Dippel, Andrew
Hutchinson, Mark
Huang, Fengying
Aleti, Vineela
Niu, Chendi
Qian, Chen
Denham, Jessica
Ferreira, Sofia
Pradhan, Pallab
Penney, Mark
Wang, Chunlei
Liu, Wenhai
Walseng, Even
Mazor, Yariv
Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C(H)1-C(λ) interface
title Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C(H)1-C(λ) interface
title_full Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C(H)1-C(λ) interface
title_fullStr Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C(H)1-C(λ) interface
title_full_unstemmed Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C(H)1-C(λ) interface
title_short Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C(H)1-C(λ) interface
title_sort robust production of monovalent bispecific igg antibodies through novel electrostatic steering mutations at the c(h)1-c(λ) interface
topic Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629431/
https://www.ncbi.nlm.nih.gov/pubmed/37930310
http://dx.doi.org/10.1080/19420862.2023.2273449
work_keys_str_mv AT bagertjohnd robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface
AT oganesyanvaheh robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface
AT chiangchii robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface
AT iannottimike robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface
AT linjia robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface
AT yangchunning robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface
AT paynesterling robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface
AT mcmahonwill robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface
AT edwardssamuel robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface
AT dippelandrew robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface
AT hutchinsonmark robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface
AT huangfengying robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface
AT aletivineela robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface
AT niuchendi robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface
AT qianchen robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface
AT denhamjessica robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface
AT ferreirasofia robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface
AT pradhanpallab robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface
AT penneymark robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface
AT wangchunlei robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface
AT liuwenhai robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface
AT walsengeven robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface
AT mazoryariv robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface